ArticleJournal of virology2003
High-frequency genetic recombination and reactivation of orthopoxviruses from DNA fragments transfected into leporipoxvirus-infected cells.
Article in Journal of virology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Rapid Generation of Recombinant Poxviruses Using CRISPR/Cas9 Gene Editing.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Poxvirus Recombination.Pathogens (Basel, Switzerland) · 2022Review
- Capripoxviruses, leporipoxviruses, and orthopoxviruses: Occurrences of recombination.Frontiers in microbiology · 2022Review
- Smallpox in the Post-Eradication Era.Viruses · 2020Review
- Synonymous genome recoding: a tool to explore microbial biology and new therapeutic strategies.Nucleic acids research · 2019Review
- Generation of recombinant MVA-norovirus: a comparison study of bacterial artificial chromosome- and marker-based systems.Virology journal · 2019Article
- Poxviruses as Gene Therapy Vectors: Generating Poxviral Vectors Expressing Therapeutic Transgenes.Methods in molecular biology (Clifton, N.J.) · 2019Article
- Synthetic viruses-Anything new?PLoS pathogens · 2018Article
- Synthetic horsepox viruses and the continuing debate about dual use research.PLoS pathogens · 2018Article
- Vaccinia-based vaccines to biothreat and emerging viruses.Biotechnology & genetic engineering reviews · 2018Review
- CRISPR/Cas9-Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Development.Viruses · 2018Review
- Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments.PloS one · 2018Article
- Genome scale patterns of recombination between coinfecting vaccinia viruses.Journal of virology · 2014Article
- Article
- Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice.Journal of virology · 2010Article
- Article
- Killing a killer: what next for smallpox?PLoS pathogens · 2010Review
- Marker rescue mapping of the combined Condit/Dales collection of temperature-sensitive vaccinia virus mutants.Virology · 2008Article
- Phenotypic analysis of a temperature sensitive mutant in the large subunit of the vaccinia virus mRNA capping enzyme.Virology · 2008Article
- The vaccinia virus E8R gene product is required for formation of transcriptionally active virions.Virology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poxvirus DNA is not infectious because establishing an infection requires the activities of enzymes packaged in the virion. This barrier can be overcome by transfecting virus DNA into cells previously infected with another poxvirus, since the resident virus can provide the trans-acting systems needed to reactivate transfected DNA. In this study we show that cells infected with a leporipoxvirus, Shope fibroma virus (SFV), can reactivate vaccinia virus DNA. Similar heterologous packaging systems which used fowlpox-infected cells to reactivate vaccinia virus have been described, but SFV-infected cells promoted a far more efficient reaction that can produce virus titers exceeding 10(6) PFU/ micro g of transfected DNA. SFV-promoted reactions also exploit the hyperrecombinogenic systems previously characterized in SFV-infected cells, and these coupled recombination and reactivation reactions could be used to delete nonessential regions of the vaccinia virus genome and to reconstruct vaccinia virus from overlapping DNA fragments. SFV-catalyzed recombination reactions need only two 18- to 20-bp homologies to target PCR amplicons to restriction enzyme-cut vaccinia virus vectors, and this reaction feature was used to rapidly clone and express a gene encoding fluorescent green protein without the need for plaque purification or selectable markers. The ability of SFV-infected cells to reactivate fragments of vaccinia virus was ultimately limited by the number of recombinational exchanges required and one cannot reconstruct vaccinia virus from multiple PCR fragments spanning essential portions of the genome. These observations suggest that recombination is an integral part of poxvirus reactivation reactions and provide a useful new technique for altering the structure of poxvirus genomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.